Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/2010

01-05-2010 | Short Communication

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

Authors: Cornelia L. Trimble, Shiwen Peng, Christopher Thoburn, Ferdynand Kos, T. C. Wu

Published in: Cancer Immunology, Immunotherapy | Issue 5/2010

Login to get access

Abstract

Essentially all squamous cervical cancers and their precursor lesions, high grade cervical intraepithelial neoplasia (CIN2/3), are caused by persistent human papillomavirus (HPV) infection. However, not all CIN2/3 lesions progress to cancer. In a brief, observational study window monitoring subjects with CIN2/3 from protocol entry (biopsy diagnosis) to definitive therapy (cervical conization) at week 15, in a cohort of 50 subjects, we found that 26% of CIN2/3 lesions associated with HPV16, the genotype most commonly associated with disease, underwent complete histologic regression. Nonetheless, HPV16-specific T cell responses measured in peripheral blood obtained at the time of study entry and at the time of conization were marginally detectable directly ex vivo, and did not correlate with lesion regression. This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation.
Literature
1.
go back to reference Frazer IH, Lowy DR, Schiller JT (2007) Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 37(Suppl 1):S148–S155CrossRefPubMed Frazer IH, Lowy DR, Schiller JT (2007) Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 37(Suppl 1):S148–S155CrossRefPubMed
2.
go back to reference Bosch F et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802CrossRefPubMed Bosch F et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802CrossRefPubMed
3.
go back to reference Hudson J et al (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519–526PubMed Hudson J et al (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519–526PubMed
4.
go back to reference Werness B, Levine A, Howley P (1990) Association of human papillomavirus types 16 and 18 proteins with p53. Science 248:76–79CrossRefPubMed Werness B, Levine A, Howley P (1990) Association of human papillomavirus types 16 and 18 proteins with p53. Science 248:76–79CrossRefPubMed
5.
go back to reference Melnikow J et al (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727–735CrossRefPubMed Melnikow J et al (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727–735CrossRefPubMed
6.
go back to reference Trimble CL et al (2005) Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11(13):4717–4723CrossRefPubMed Trimble CL et al (2005) Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11(13):4717–4723CrossRefPubMed
7.
go back to reference Schlecht NF et al (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95(17):1336–1343PubMed Schlecht NF et al (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95(17):1336–1343PubMed
8.
go back to reference Kanodia S, Da Silva DM, Kast WM (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122(2):247–259CrossRefPubMed Kanodia S, Da Silva DM, Kast WM (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122(2):247–259CrossRefPubMed
9.
go back to reference Currier JR et al (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1–2):157–172CrossRefPubMed Currier JR et al (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1–2):157–172CrossRefPubMed
10.
go back to reference Gravitt PE (2003) Reproducibility of HPV16 and HPV18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 112(1–2):23–33CrossRefPubMed Gravitt PE (2003) Reproducibility of HPV16 and HPV18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 112(1–2):23–33CrossRefPubMed
Metadata
Title
Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3
Authors
Cornelia L. Trimble
Shiwen Peng
Christopher Thoburn
Ferdynand Kos
T. C. Wu
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0806-4

Other articles of this Issue 5/2010

Cancer Immunology, Immunotherapy 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine